PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1527307
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1527307
Global Endobronchial Valves Market is valued approximately at USD 171.15 million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.9% over the forecast period 2024-2032. Endobronchial valves are medical devices used primarily to treat severe emphysema, a form of chronic obstructive pulmonary disease (COPD). These small, one-way valves are implanted in the airways of the lungs using a minimally invasive bronchoscopy procedure. Once in place, they allow air to exit the over-inflated, diseased parts of the lungs but prevent air from entering these areas. This process reduces lung hyperinflation and redirects airflow to healthier parts of the lung, thereby improving breathing efficiency. By relieving pressure and reducing the volume of the diseased lung sections, endobronchial valves help enhance overall lung function, alleviate symptoms like shortness of breath, and improve the patient's quality of life. The procedure is generally considered for patients who are not candidates for more invasive surgical interventions like lung volume reduction surgery or lung transplantation. The increasing prevalence of lung-related health issues, notably chronic obstructive pulmonary disease (COPD), is driving the demand for innovative medical devices like endobronchial valves. COPD is a leading cause of mortality, claiming approximately 3 million lives annually, according to the American Journal of Respiratory and Critical Care Medicine. This alarming statistic underscores the need for effective treatment options, including minimally invasive procedures facilitated by endobronchial valves, which are increasingly preferred over traditional open surgeries due to reduced trauma.
The Endobronchial Valves Market is also bolstered by the significant number of clinical trials focused on COPD, as reported by the WHO International Clinical Trials Registry Platform, with over 600 ongoing studies. This active research landscape highlights the growing interest and investment in discovering new treatment methodologies for COPD, which is expected to propel the endobronchial valves market forward. For instance, a study published in MDPI in November 2022 emphasized the advancements in bronchoscopic management for COPD, reflecting the ongoing efforts to enhance therapeutic options in this field. Moreover, rising awareness about bronchoscopic lung volume reduction as a viable treatment for lung-related health issues is further driving the market. However, the high cost associated with bronchoscopic valves, driven by the limited number of market players, poses a challenge to broader market expansion.
The key regions considered for the Global Endobronchial Valves Market study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa, North America held the largest market share in 2023, driven by the high prevalence of COPD and robust healthcare infrastructure. The region's focus on clinical trials and innovative treatments, alongside FDA approvals for devices like Zephyr and Spiration valves, reinforces its market dominance. The Asia Pacific region is expected to grow rapidly due to the aging population and increasing incidence of lung diseases, driven by factors such as air pollution and occupational hazards.